The Compliance Roadmap

The Compliance Roadmap

Mark Scallon, Senior Principal, Commercial Compliance, IQVIA

As regulatory changes continue in the EU and the U.S., life sciences companies will need to focus more on rigor and reproducibility with respect to non-clinical, pre-clinical, clinical data, and post-market data, in addition to the subsequent documentation and audit challenges. (more…)

Supplier Risk and its Impact on Corporate Risk

Supplier Risk and its Impact on Corporate Risk

Kari Miller, Regulatory and Product Management Leader, Pilgrim Quality Solutions, an IQVIA company

Risk continues to be a major focus in most businesses today, regardless of industry. In the past few years, Life Sciences organizations have seen a steady rise in supply chain issues resulting in lost market caps, recalls, regulatory fines, and other financial impacts valued in the billions of dollars. Subsequently, the standards organizations and regulators around the globe have taken note and responded accordingly. So it’s no surprise that minimizing business and operational risks, as well as legal and regulatory compliance, is on every executive’s mind, and for good reason.

Supplier risk, put simply, is the probability associated with a supplier causing an interruption in an organization’s supply chain by impacting the availability of products and services within that supply chain. Supplier impact, at a minimum, effects two legs of the three-legged Governance, Risk, and Compliance (GRC) stool: those two legs are Risk and Compliance. The impact of suppliers on an enterprise can be significant. (more…)

Quality within the BioPharma Industry Landscape

Quality within the BioPharma Industry Landscape

Florian Czaszewicz, Industry Solutions Consultant, Pilgrim Quality Solutions, an IQVIA company

The American Society for Quality, touted as the “Global Voice of Quality,” states that manufacturers in the pharmaceutical industry are always working to balance the demands of meeting global regulations and production costs, in an effort to produce the most innovative research and development while also producing safe, reliable prescription drugs. As a biopharmaceutical industry veteran, I know the challenge is real. In fact, when illustrating a graphic representation of the Biopharma industry’s information management landscape, as I see it, the depiction is quite dense and complex. (more…)

A Deviation by Any Other Name

A Deviation by Any Other Name

Kari Miller, Regulatory and Product Management Leader, Pilgrim Quality Solutions, an IQVIA company

What’s in a name? Depending on industry, a word can have very precise meaning. Look up the word “deviation” on the internet and the first definition to appear reads: noun, The action of departing from an established course or accepted standard. Statisticians use the term to define “The act of deviating” or “Deviation from a norm”.

If you search for the definition of “deviation” as applied in the Pharmaceutical industry, you’ll find some variation of “Unexpected departure from an approved instruction, procedure, established standard or specification.” In other words, “deviation” is not a desirable term in the Quality lexicon. (more…)

Continuing Education in the Quality Space

Continuing Education in the Quality Space

Lynn Willis, Partner Enablement and Training Manager, Pilgrim Quality Solutions, an IQVIA company

An important facet of any organization’s quality efforts is the knowledge of its personnel. The depth of each employee’s knowledge and skills contributes to the company’s ability to achieve its mission and goals. Conversely, employees who do not have the knowledge to perform their day-to-day functions pose a quality risk. This equation applies as much to long-time employees as to new hires. (more…)

Ready your Internal Audits for ISO 13485:2016

Ready your Internal Audits for ISO 13485:2016

Bernard Jee, Product Manager, Pilgrim Quality Solutions, an IQVIA company

Time is running out – one month and counting. Manufacturers must meet the requirements of ISO 13485:2016 by February 28, 2019 to maintain their certification.

If you’re responsible for planning and carrying out your company’s internal audits, you know how much planning and effort it takes to monitor your quality system for GMP and ISO compliance. As your quality system has matured, you’ve probably noticed that certain sites, departments, or processes require more of your attention. (more…)

19 Quality Compliance Resolutions for 2019

19 Quality Compliance Resolutions for 2019

Be the change you want to see in 2019. We asked members of the Pilgrim blogging community to tap into their subject matter expertise to compile a list of some behaviors or routines that have been proven to fuel success. Consider these 19 suggested resolutions for Quality and Compliance practices, and think about how you can turn them into daily habits to drive your organization’s continuous improvement this year and beyond. (more…)

Happy Holidays from the Pilgrim Quality Blog Team

Happy Holidays from the Pilgrim Quality Blog Team

It has been our pleasure this year to share with you our perspectives on the latest topics in quality, compliance, and risk management. We wish you a wonderful holiday season and a prosperous 2019.
(more…)

MedTech Company of the Year 2018 Finalists

MedTech Company of the Year 2018 Finalists

MDDI Staff, MD+DI Magazine

Medical Device and Diagnostics Industry (MD+DI) Magazine announced it’s 2018 list of finalists for MedTech Company of the Year. The industry publication named Boston Scientific among the list of 10 companies that have “risen above the rest in 2018.” For over a decade, both IQVIA and Pilgrim Quality Solutions, an IQVIA company, have enjoyed a long-standing relationship with industry leading Boston Scientific. MD+DI cited Boston Scientific’s aggressive Mergers & Acquisition strategy. In July, the company’s CEO Mike Mahoney “reassured investors that the firm’s M&A appetite was part of a very well laid out plan.” (more…)

Proactive Post-Market Surveillance: Medical Devices and IVDs

Proactive Post-Market Surveillance: Medical Devices and IVDs

Phil Johnson, Senior Principal, Quality and Compliance Services, IQVIA

Designing the organization and process for the future

Post-market surveillance in Medical Devices & IVDs (MedTech) has traditionally been reactive. It has focused on investigation and reporting adverse events, device malfunctions, or patient injuries in order to trigger product returns, modifications, exchanges, and recalls as necessary. However, as medical device complexity increases, Post-market surveillance will need to be more rigorous, leading to earlier detection of potential product failures in the field.

Regulatory authorities are starting to emphasize the importance of Post-market surveillance plans that are based on proactive data gathering and analysis, rather than relying on reactive data gathering once a post-market event has been reported. To meet these needs, manufacturers should take a risk-based approach when considering clinical and post-market planning. (more…)